Drug Profile


Alternative Names: BrdU; BrdUrd; BUdR; Neomark; NSC 38297

Latest Information Update: 19 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer INSYS Therapeutics, Inc; National Cancer Institute (USA)
  • Class Antineoplastics; Antivirals; Diagnostic agents; Pyrimidine nucleosides; Radiation-sensitising agents; Radiosensitisers; Small molecules
  • Mechanism of Action Antimetabolites; DNA modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Brain cancer; Breast cancer

Most Recent Events

  • 30 Jan 2003 Discontinued - Phase-III for Brain cancer in Canada (IV)
  • 30 Jan 2003 Discontinued - Preregistration for Brain cancer in USA (IV)
  • 30 Jan 2003 Discontinued - Preregistration for Breast cancer diagnosis in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top